Advances In Care podcast

Player FM - Internet Radio Done Right

1,691 subscribers

Vor fünfundzwanzig Wochen hinzugefügt

Inhalt bereitgestellt von NewYork-Presbyterian. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von NewYork-Presbyterian oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

Curated Questions: Conversations Celebrating the Power of Questions!

1
Ashley Kirsner 1:40:41

vor 4 Tagen1:40:41

Später Spielen

Listen

Gefällt mir

Geliked

1:40:41

Episode Notes [00:00] The Power of Vulnerability [01:57] Meet Ashley Kirsner [03:55] The Impact of Active Listening [05:02] A Transformative Call [06:25] The Magic of Open-Ended Questions [13:28] The Role of Basic Needs in Emotional Well-being [17:10] The Birth of Skip the Small Talk [25:18] The First Skip the Small Talk Event [28:39] The Evolution of Skip the Small Talk [32:56] Online Events During COVID-19 [34:58] Work At An Anxiety Lab [38:08] The Importance of Positive Questions [42:40] The Power of Repeated Questions [45:33] Attending a Skip the Small Talk Event [46:14] The Speed Dating Format [47:21] Encouraging Anxious Participants [48:45] The Power of Sharing Deeply [49:32] Consistent Findings on Vulnerability [50:13] Understanding Oversharing [51:11] Structure and Time Management [52:18] Facilitators and Norms [53:12] Contact Information Norms [55:06] Intentional Iteration and Safety [56:37] The Role of Participants [59:01] Financial Accessibility and Investment [01:00:43] Balancing Accessibility and Compensation [01:01:49] Compensating Facilitators [01:04:39] Physiological Benefits of Deep Conversations [01:07:00] Research on Loneliness and Connection [01:09:02] The Impact of Loneliness on Health [01:10:41] The Role of Sleep in Connection [01:13:42] The Importance of Group Interactions [01:15:10] The Power of Intentional Conversations [01:20:26] Learning from Gathering Experts [01:23:19] Right Now Question & Following Curiosity [01:30:18] Where You Can Find Skip The Small Talk [01:35:45] Takeaway Thoughts & Questions Resources Mentioned Skip The Small Talk Chris Voss Finding Good with Brian Fretwell Dr. Nicholas Epley DBT - Dialectical Behavioral Therapy Brene Brown How We Gather by Priya Parker Power of Ritual by Casper ter Kuile How We Gather by Dr. Angie Thurston - Harvard Divinity School Death of Rasputin Harvard Graduate School of Education Harvard Wharton Business School MIT GE Aviation Act Blue Beauty Pill Producer Ben Ford Questions Asked When did you first understand the power of questions? How would this possibly work? What are we doing here? How could this possibly be effective? What is it that asking questions actually does for us? In this deep end of the pool, for what you experience as a suicide hotline counselor, what does that look like? How did that impact you? Were there questions that you found most impactful on that end? Are you feeling suicidal right now? Do you have a weapon? Do you have a plan? Do you have any objects to complete that plan with you right now? Are you comfortable being in a different room from it while we're having this conversation? When's the last time you slept? When's the last time you ate? Can we get some food in you? Can we take a walk? Do they know anything you're experiencing right now? If the roles were reversed and it were your partner or your cousin or your parent who were going through something like this, would you want them to tell you about it? Do you think they wanna know if you're going through a tough time? What if we had a space where we were all on the same page? Can you take a moment to go home and be a little more vulnerable with your roommate, partner, family, or neighbors? Can you take that skill with you into the rest of your life? How are you doing right now? How did you decide to do your first skip-the-small-talk event? When's the next one gonna be? Is this even possible? How do you have people switch partners in a way that makes sense online? How do we do this? What do you got for us? How do we do this for like hundreds of people? Can you talk about that story of where you pulled the questions from, and why you chose the different questions that you did? Where do you live? What do you like about where you live? What's the worst thing you've ever experienced? When's the last time you cried? When's the last time you experienced awe? What's something you're proud of that you don't normally get to share with people or that might not be on a resume? Specifically asking what are pieces of yourself that you don't normally get to share? What is a favorite ice cream? What was something that this organization has done right to help you? What do you think it is about the structure that allows for that to happen? What other elements are at play here? Finances would be a barrier, can you help me out? Do you wanna do it for free? Due to your position in society, does it make you more or less likely to go to prison? How can we do subtle things so that you don't have to necessarily out yourself as having an invisible disability, but still get your needs met? How can we make people with marginalized identities feel comfortable opening up? How do we make those spaces feel safer? What is your right now question? What makes an experience awesome? What makes storytelling awesome? Why was this moment so powerful? Why do we dim the lights a little at dinner parties What little things can you do to trick your physiology to be more immersed in an experience? Does doing a new novel activity with someone, trick your brain into being more excited about hanging out with someone? How can you make these memories more tactile? What does the tablecloth feel like? What do the napkins feel like? Can you just do five more of these? Can we do this throughout the year? What assumptions are you making about how much others want to know about your inner world, and how might testing those assumptions change your relationships? How might your community benefit from structured opportunities to practice deeper connection, and what role could you play in creating those spaces? If you treated meaningful conversation as essential to your health, as sleep or exercise, how would that change your daily priorities and choices? Are your questions designed to extract information or to create conditions where others can share the best parts of themselves?…

Advances in Care

Serie-Home•Feed

On Advances in Care, epidemiologist and science communicator Erin Welsh sits down with physicians from NewYork-Presbyterian hospital to discuss the details behind cutting-edge research and innovative treatments that are changing the course of medicine. From breakthroughs in genome sequencing to the backstories on life-saving cardiac procedures, the work of these doctors from Columbia & Weill Cornell Medicine is united by a collective mission to shape the future of health care and transform the lives of their patients. Erin Welsh, who also hosts This Podcast Will Kill You, gets to the heart of her guests’ most challenging and inventive medical discoveries. Advances in Care is a show for health careprofessionals and listeners who want to stay at the forefront of the latest medical innovations and research. Tune in to learn more about some of medicine’s greatest leaps forward. For more information visit nyp.org/Advances

41 Episoden

Advances in Care

1,691 subscribers

updated vor 11 Tagen

Serie-Home•Feed

41 Episoden

Όλα τα επεισόδια

Advances in Care

1
Solving Long Term Side Effects of Chemotherapy Cancer Treatments 16:07

vor 11 Tagen16:07

16:07

On this episode of Advances in Care , host Erin Welsh hears from Dr. Meghna Trivedi, an oncologist at NewYork-Presbyterian and Columbia, who is spearheading new research to assess cancer patients’ risk of developing chemotherapy induced peripheral neuropathy–an all too common side effect of cancer treatment. Dr. Trivedi describes a study that she and her team undertook to identify and assess patient risk for developing a specific type of chemotherapy-induced neuropathy called TIPN, which is caused by taxanes, a commonly used chemotherapy drug. Based on this SWOG trial, known as S1714, physicians are better able to monitor at-risk patients for these side effects and adjust their treatment regimens accordingly. Then, Dr. Trivedi explains how her team–also led by Dr. Daniel Hertz, PharmD, PhD at the University of Michigan–was recently awarded a prestigious R37 grant to identify a biomarker for TIPN. This study, which she co-leads with Dr. Daniel Hertz, PharmD, PhD at the University of Michigan, will help doctors understand the mechanisms for why TIPN develops in the first place, and will be a critical step forward in creating targeted therapies to treat this disease before it starts. Finally, Dr. Trivedi dives into the clinical trials her team is currently conducting to identify new therapeutic approaches to address and prevent the effects of neuropathy, such as cryotherapy. *** Dr. Meghna Trivedi, is a medical oncologist at NewYork-Presbyterian and co-leads the Hereditary Breast and Ovarian Cancer Program at Columbia’s Herbert Irving Comprehensive Cancer Center, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties. Dr. Trivedi’s research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals. To learn more about the SWOG trial visit swog.org/clinical-trials/s1714 For more information visit nyp.org/Advances…

Advances in Care

1
Pioneering a First in Robotic Liver Transplant 17:53

vor 25 Tagen17:53

17:53

On this episode of Advances in Care , host Erin Welsh hears from Dr. Juan P. Rocca, a transplant surgeon at NewYork-Presbyterian and Weill Cornell Medicine, who recently led the first fully robotic liver transplant in New York. Dr. Rocca details the recent developments in robotic surgery at Weill Cornell Medicine’s Division of Liver Transplantation and Hepatobiliary Surgery, including an ongoing push to advance from laparoscopic and open surgical methods, and now to robotics. He explains why the robotic approach is optimal for complex liver surgeries, and discusses how he and his team have been training to make robotic living donor hepatectomies a standard in their department. Then, Dr. Rocca breaks down the process of the liver transplant operation that became the first fully robotic execution in New York. He describes the most critical steps of the procedure, how it felt to achieve this milestone, and the example that he hopes to set for other institutions beyond NewYork-Presbyterian and Weill Cornell Medicine. *** Dr. Juan Rocca is the Surgical Director of the Weill Cornell Liver Cancer Program and an attending surgeon in the Division of Liver Transplantation and Hepatobiliary Surgery at NewYork-Presbyterian and Weill Cornell Medicine. He was an early adopter of laparoscopic techniques for major hepatectomy and later transitioned to robotic surgery for complex liver procedures in patients with chronic liver disease. At Weill Cornell Medicine, he led the development of a comprehensive robotic liver surgery program, encompassing liver cancer resections, living liver donation, and the state's first fully robotic liver transplant For more information visit nyp.org/Advances…

Advances in Care

1
Rise in Early-Onset Colon Cancer Being Studied Through Single-Cell Sequencing 15:46

vor 6 weeks15:46

15:46

On this episode of Advances in Care , host Erin Welsh and Dr. Joel Gabre, a gastroenterologist at NewYork-Presbyterian and Columbia who specializes in cancer care, discuss the ongoing rise in colorectal cancer rates among younger individuals. Dr. Gabre lays out trends observed by the medical community in colorectal cancer rates, including the increasing likelihood by birth cohort for patients to develop this disease. He also talks about the main differences in colorectal cancer for patients from these different cohorts, most notably the location where cancers are likely to develop in the colon. Dr. Gabre also shares some of the leading hypotheses for why colon cancer rates are rising in younger people, and that clinicians and researchers are focused on searching for answers to improve prevention and treatment options. He gets into the importance of the western diet in developing these forms of cancer and shares details about his team’s recent findings regarding changes at the cellular level that could be contributing to the accelerated growth of these cancers. Finally, Dr. Gabre speaks to his personal experiences as a gastroenterologist who has seen first hand the rise in colon cancer rates among his patients. He shares a story of what motivated him to begin researching the cellular mechanisms driving colorectal cancer in young people, with the hope of finding a solution. *** Dr. Joel Gabre is a gastroenterologist and GI cancer genetics specialist interested in studying diseases of the upper GI tract with particular focus on the esophagus. He completed his undergraduate degree at Johns Hopkins University in biophysics, medical degree at the University of Maryland, internal medicine residency at the University of Cincinnati, and gastroenterology fellowship and post-doctoral research fellowship at the University of Pennsylvania, where he was chief GI fellow. He currently serves as Assistant Professor of Medicine at Columbia University Irving Medical Center in the Division of Digestive and Liver Diseases and as a member of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian and Columbia. For more information visit nyp.org/Advances…

Advances in Care

1
How GLP-1s Provide New Options to Manage Heart Disease 15:25

vor 8 weeks15:25

15:25

On this episode of Advances in Care , host Erin Welsh talks to Dr. David Majure, a cardiologist and heart failure specialist at NewYork-Presbyterian and Weill Cornell Medicine. Together they discuss the rapid rise in GLP-1 research over the past few years, indicating new applications for these therapies to help a wide variety of patients. They explore how GLP-1s work on a molecular level, and how using them to treat diabetes revealed other potential cardiovascular benefits. Dr. Majure highlights several recent studies that explore the effects of semaglutide and tirzepitide on patients with heart failure, particularly those with preserved ejection fraction. This new research demonstrates that GLP-1s can be an effective treatment beyond diabetes, helping with weight management and cardiovascular disease. Dr. Majure breaks down what effects doctors can expect to see in patients who are prescribed GLP-1s, including the difference in outcomes between semaglutide and tirzepatide. He also notes the potential risk factors, cautioning that while these medications are effective, the focus in addressing heart disease should always remain on prevention. *** Dr. David Majure is the Medical Director of the Heart Transplant Service at NewYork-Presbyterian and Weill Cornell Medicine. He specializes in the care of patients with heart failure, patients requiring or who have a heart transplant or ventricular assist device (LVAD), and patients with pulmonary hypertension. He has contributed extensively to research and has served as principal investigator in multiple clinical trials, exploring all aspects of advanced heart failure. Dr. Majure has been recognized as a Castle Connolly Top Doctor since 2020. For more information visit nyp.org/Advances…

Advances in Care

1
Developing Precise Diagnostics for this Common Genetic Heart Disease 16:44

vor 10 weeks16:44

16:44

On this episode of Advances in Care , host Erin Welsh and cardiologist Dr. Diala Steitieh discuss the current landscape of care for hypertrophic cardiomyopathy — or HCM — the most common genetic heart disorder. Dr. Steitieh outlines the advantages of genetic screenings for patients who have HCM, along with the symptoms and risks if the condition is left undiagnosed or unmanaged. She expands on the importance of understanding obstructive vs. non-obstructive conditions and the importance of making a precise diagnosis to get a clear sense of each patient’s severity. Dr. Steitieh and her team recently implemented a new approach to their diagnostic imaging protocol called goal-directed Valsalva. With this emerging tool in the landscape of cardiology, they are able to get a better sense of an obstruction impacting blood flow, and ultimately offer a wider variety of treatment options. Beyond diagnosis, Dr. Steitieh also shares her excitement about updates to the management of HCM, including recently approved drugs and new guidelines regarding sports & exercise. She and her team at Weill Cornell Medicine are in the process of becoming a designated Hypertrophic Cardiomyopathy Association Center of Excellence, a development that Dr. Steitieh hopes will improve access to care for patients in New York and beyond. *** Dr. Diala Steitieh is an Assistant Professor of Clinical Medicine, and the Director of the Hypertrophic Cardiomyopathy program in the Division of Cardiology at Weill Cornell Medical College and New York Presbyterian Hospital. She has a background in sports cardiology and also cares for patients with a wide array of cardiovascular diseases, including coronary disease and valvular heart disease. Dr. Steitieh also serves as an attending physician on the inpatient services at NewYork-Presbyterian Hospital, including the intensive care unit and cardiac units. For more information visit nyp.org/Advances…

Advances in Care

1
A Landmark Surgery that Saved Three Children with One Heart 22:41

vor 12 weeks22:41

22:41

On this episode of Advances in Care , host Erin Welsh talks to Dr. Andrew Goldstone and Dr. David Kalfa, pediatric cardiac surgeons at NewYork-Presbyterian and Columbia, about their groundbreaking heart transplant that saved the lives of three separate children. It was the first time doctors at NewYork-Presbyterian Morgan Stanley Children’s Hospital performed a split-root domino partial heart transplant. In this procedure, one child was transplanted with a new heart and their original heart was used to donate living pulmonary and aortic valves to two separate recipients in need. Dr. Goldstone, Dr. Kalfa and the rest of the team at NewYork-Presbyterian and Columbia had previous experience with a handful of domino partial heart transplants where one patient is transplanted with a new heart and another receives a valve from the explanted heart. Those experiences helped prepare for the split-root domino, which took nearly 24 hours of extremely coordinated care. In addition to their efforts to increase the number of domino heart transplants being done, physician-researchers at the institution are leading new studies that are also helping improve living valve procurement and storage, allowing more children to receive heart valves that will grow with them and require less surgeries. *** Dr. Andrew Goldstone is the Surgical Director of Heart Transplant and Mechanical Circulatory Support and Director of the Valve Transplant Program at Columbia and NewYork-Presbyterian. He has been recognized nationally and internationally for his clinical and basic science research. In the lab, he focuses on mechanisms underlying collateral artery formation and cardiac regeneration. His long-term goal is to continue adding high-level evidence to better inform the surgical treatment of pediatric and adult cardiovascular disease. Dr. David Kalfa is a Board-certified cardiothoracic surgeon with a subspecialization in pediatric cardiac surgery. He is also a researcher focusing in the field of growing heart valves and growth accommodating heart valves. For more information visit nyp.org/Advances…

Advances in Care

1
Preventing Unnecessary C-Sections through Labor Induction Research 16:26

vor 14 weeks16:26

16:26

On this episode of Advances in Care , host Erin Welsh and Dr. Moeun Son, OB/GYN and Maternal-Fetal Medicine Specialist at NewYork-Presbyterian and Weill Cornell Medicine, discuss Dr. Son’s perspective on treating patients who face a high-risk pregnancy and might need a caesarian delivery. Dr. Son explains that even though c-sections are a highly common and safe delivery option for many women, they’re not often not the top option in a woman’s birth plan, and don’t carry the same benefits as natural labor. She outlines the standard methods for labor induction to prevent the necessity of a c-section, which includes the administration of a synthetic form of the hormone oxytocin. Beyond her work with patients, Dr. Son is also passionate about researching alternative methods for labor induction and preventing unnecessary c-sections. She and her colleagues designed a study to promote natural oxytocin release through nipple stimulation – mimicking breastfeeding through the use of a hospital grade breast pump. The success of that treatment eventually led to the The Stimulation To Induce Mothers Study – or STIM Study. Today, it’s an ongoing trial that aims to compare the effectiveness of natural oxytocin versus synthetic oxytocin in helping women give birth vaginally. Dr. Son hopes that this research will broaden birthing options for women experiencing a high-risk pregnancy, and add more safe and effective treatment methods to the field of women’s health. *** Dr. Moeun Son is board-certified in Obstetrics and Gynecology and Maternal-Fetal Medicine. In her practice, she focuses on women with high-risk pregnancies, from pre-existing maternal conditions to babies with health anomalies. She is the principal investigator on many clinical research projects, including various randomized clinical trials. Dr. Son also serves as the Program Director of the MFM Fellowship Program at Weill Cornell For more information visit nyp.org/Advances…

Advances in Care

1
Innovating Shoulder Surgery through Tendon Transfers 20:17

vor 16 weeks20:17

20:17

On this episode of Advances in Care , host Erin Welsh and Dr. Karan Dua, an orthopedic surgeon at NewYork-Presbyterian and Columbia, discuss novel approaches to shoulder surgery, including transferring donor tendons to the upper extremity with arthroscopic tools. Dr. Dua shares his passion developing personalized treatments that get to the root cause of a wide range of shoulder issues. Dr. Dua explains the importance of the scapula and what happens when its range of motion is abnormal, or out of alignment. He talks about his process for balancing the scapula to relieve pain in his patients, who are often young and suffering from pain due to injuries from work or sports. He also discusses the difference between shoulder replacement – a common treatment for patients with arthritis – and shoulder reanimation. Dr. Dua is skilled in shoulder reanimation, and describes how he performs tendon transfers to preserve a patient’s joints and allow them to restore movement of their shoulder. Using arthroscopic instruments, Dr. Dua collects a donor tendon either from another part of the patient’s body or from a cadaver, and replaces the injured tendon with a healthy one. Dr. Dua hopes to develop a robust scapula program at NewYork-Presbyterian and Columbia that offers targeted treatment for patients suffering from a range of upper extremity issues. *** Dr. Karan Dua is an orthopedic surgeon specializing in the treatment of structures affecting the form and function of the entire arm. He is dual trained in hand, upper extremity, and microvascular surgery, and in shoulder and elbow surgery. He has an avid interest in open and arthroscopic tendon transfers of the shoulder, complex reconstructions after failed surgery, arthroscopic and minimally invasive techniques for nerve decompression including the brachial plexus and around the shoulder blade, and tendon transfers for scapular winging. For more information visit nyp.org/Advances…

Advances in Care

1
Exploring Psychedelics as the Next Wave of Psychiatric Innovation 19:13

vor 18 weeks19:13

19:13

On this episode of Advances in Care , host Erin Welsh first hears from Dr. Richard Friedman, a clinical psychiatrist at NewYork-Presbyterian and Director of the Psychopharmacology Clinic at Weill Cornell Medicine. Using his background in psychopharmacology, Dr. Friedman distinguishes between psychedelics and standard antidepressants like SSRIs and SNRIs, explaining the various mechanisms in the brain that respond uniquely to psychedelic compounds. While both methods of treatment involve serotonin stimulation, psychedelics are the only known drug to shut off the brain’s Default Mode Network, which is the group of brain regions that are active when a person is not thinking about external stimuli. Dr. Friedman also identifies that the challenge of proving efficacy of psychedelic therapy lies in the question of how to design a clinical trial that gives patients a convincing placebo. To learn more about the challenges of trial design, Erin also speaks to Dr. David Hellerstein, a research psychiatrist at NewYork-Presbyterian and Columbia. Dr. Hellerstein contributed to a 2022 trial of synthetic psilocybin in patients with treatment resistant depression. He and his colleagues took a unique approach to dosing patients so that they could better understand the response rates of patients who use psychedelic therapy. The results of that trial underscore an emerging pattern in the field of psychiatry – that while psychedelic therapy has its risks, it’s also a promising alternative treatment for countless psychiatric disorders. Dr. Hellerstein also shares more about the future of clinical research on psychedelic therapies to potentially treat a range of mental health disorders. *** Dr. Richard Friedman is a professor of clinical psychiatry and is actively involved in clinical research of mood disorders. In particular, he is involved in several ongoing randomized clinical trials of both approved and investigational drugs for the treatment of major depression, chronic depression, and dysthymia. Dr. David J. Hellerstein directs the Depression Evaluation Service at Columbia University Department of Psychiatry, which conducts studies on the medication and psychotherapy treatment of conditions including major depression, chronic depression, and bipolar disorder. For more information visit nyp.org/Advances…

Advances in Care

1
Detecting Parkinson’s Disease Sooner with Biomarker Research 18:48

vor 20 weeks18:48

18:48

On this episode of Advances in Care , host Erin Welsh and Dr. Serge Przedborski, Chief of the Division of Movement Disorders at NewYork-Presbyterian and Columbia, discuss what happens in the brains of patients with Parkinson’s disease. Dr. Przedborski came to Columbia thirty two years ago and has spent that time researching why some neurons in the brain die while others live in people who suffer from the condition – and he’s learned a lot. With the help of the New York Brain Bank at Columbia, his lab has been able to map out what the neuronal patterns of death look like with the goal of using these brain maps to develop novel treatments that seek to address the progression of Parkinson’s rather than just treating the symptoms, which is how all current treatments work. Dr. Przedborksi also shares updates on new gene therapies that are being investigated across the institution to replace Deep Brain Stimulation – a common treatment for Parkinson’s where a wire is placed in the brain. While these gene therapy treatments are still invasive, the technology behind them is constantly improving and will likely lead to significant benefits to patients *** Dr. Przedborski’s ongoing research aims at understanding the contributions of cell-autonomous and non cell-autonomous mechanisms to neurodegeneration using both toxic and genetic experimental models of Parkinson’s Disease and ALS. In keeping with this goal, how alterations in mitochondrial biology, especially of mitochondrial dynamics and mitophagy, provoke degeneration of specific subpopulations of neurons is one of the main areas of research in the Przedborski laboratory. To what extent and by which mechanisms do non-neuronal cells, like microglia and astrocytes, participate in the demise of neurons in neurodegenerative disorders, such as Parkinson’s and ALS, represent a second main line of research in this laboratory. These research efforts are supported by federal grants from both NIH and the DoD as well as by several private agencies such as the Parkinson's Disease Foundation and the Thomas Hartman Foundation. For more information visit nyp.org/Advances…

Advances in Care

1
Newborn Gene Sequencing: Expanding Early Detection of Treatable Diseases 22:29

vor 22 weeks22:29

22:29

On this episode of Advances in Care , host Erin Welsh explores the story behind the GUARDIAN study, where thousands of newborn babies have been screened against rare disease by sequencing their genes, and looking for more conditions than any of the current standard screening panels. First, she hears from Dr. Jordan Orange, Physician-in-Chief at Morgan Stanley Children’s Hospital at NewYork-Presbyterian and Columbia, about why genetic testing is a promising way of not only catching treatable rare diseases in infants, but also expanding health equity and medical resources to marginalized populations. Erin also hears from Dr. Josh Milner, a pediatric immunologist who treated a patient with a rare form of SCID, or severe combined immune deficiency, also known as bubble boy disease that was detected in the GUARDIAN screening panel. SCID is a disease that typically occurs in 1 of 50,000 babies. But GUARDIAN caught two cases within the first 10,000 babies involved in the program, indicating that the rate of the disease might be higher than expected, and that the most accurate way to detect is through genetic screening. Dr. Steven Lobritto, a pediatric gastroenterologist, also weighs in on how genetic screening can help identify Wilson’s disease, a copper storage disorder that causes liver damage when left unchecked. And Dr. Eric Silver, a pediatric electrophysiologist, discusses how the program detected a heart rhythm disorder called Long QT Syndrome for both a newborn baby and their father. Finally, Erin gets the big-picture takeaways from Dr. Orange, who reflects on what the results of GUARDIAN could mean for the future of newborn screening and health policy, and how he hopes to see genetic testing expand research and treatment of rare diseases. For more information visit nyp.org/Advances…

Advances in Care

1
How Gene Therapies are Revolutionizing Care for Sickle Cell Disease 19:14

vor 24 weeks19:14

19:14

On this episode of Advances in Care, host Erin Welsh and Dr. Markus Mapara, Director of the Blood and Marrow Transplantation and Cell Therapy Program at NewYork-Presbyterian and Columbia, discuss the current challenges in treating sickle cell disease and how newly FDA approved gene editing treatments are leading to new treatment pathways. Dr. Mapara covers two new gene editing approaches, explaining that both involve editing stem cells and reintroducing them to patients’ bodies to curb the sickling of red blood cells. He also helps listeners to understand the difference between the two: one gene therapy uses CRISPR technology to help the body create fetal hemoglobin which mitigates cell sickling while the other uses a lentiviral vector to edit stem cells to produce anti-sickling hemoglobin that’s similar to fetal hemoglobin once reintroduced to the body. Dr. Mapara also goes into the innovative work that the Blood and Marrow Transplantation and Cell Therapy Program is doing with CAR-T cell therapies. And he shares how these advancements in treating sickle cell disease will have a significant impact on how physicians approach treating patients. *** Dr. Mapara is a Professor of Medicine at Columbia University Medical Center and the Director of the Blood and Marrow Transplantation (BMT)/Cell Therapy Program at New York Presbyterian Hospital/Columbia University Medical Center. He specializes in the care of patients with sickle cell disease and certain blood cancers (Multiple Myeloma, Amyloidosis) undergoing bone marrow transplantation and gene therapy. His research is focused on developing novel approaches to make bone marrow transplantation and cell therapy safer for patients.. For more information visit nyp.org/Advances…

Advances in Care

1
Advancing Cardiology and Heart Surgery Through a History of Collaboration 20:13

vor 26 weeks20:13

20:13

On this episode of Advances in Care , host Erin Welsh and Dr. Craig Smith, Chair of the Department of Surgery and Surgeon-in-Chief at NewYork-Presbyterian and Columbia discuss the highlights of Dr. Smith’s 40+ year career as a cardiac surgeon and how the culture of Columbia has been a catalyst for innovation in cardiac care. Dr. Smith describes the excitement of helping to pioneer the institution’s heart transplant program in the 1980s, when it was just one of only three hospitals in the country practicing heart transplantation. Dr. Smith also explains how a unique collaboration with Columbia’s cardiology team led to the first of several groundbreaking trials, called PARTNER (Placement of AoRTic TraNscatheteR Valve), which paved the way for a monumental treatment for aortic stenosis — the most common heart valve disease that is lethal if left untreated. During the trial, Dr. Smith worked closely with Dr. Martin B. Leon, Professor of Medicine at Columbia University Irving Medical Center and Chief Innovation Officer and the Director of the Cardiovascular Data Science Center for the Division of Cardiology. Their findings elevated TAVR, or transcatheter aortic valve replacement, to eventually become the gold-standard for aortic stenosis patients at all levels of illness severity and surgical risk. Today, an experienced team of specialists at Columbia treat TAVR patients with a combination of advancements including advanced replacement valve materials, three-dimensional and ECG imaging, and a personalized approach to cardiac care. Finally, Dr. Smith shares his thoughts on new frontiers of cardiac surgery, like the challenge of repairing the mitral and tricuspid valves, and the promising application of robotic surgery for complex, high-risk operations. He reflects on life after he retires from operating, and shares his observations of how NewYork-Presbyterian and Columbia have evolved in the decades since he began his residency. For more information visit nyp.org/Advances…

Advances in Care

1
Advances in Care is Back 1:35

vor 27 weeks1:35

1:35

Join host Erin Welsh as she talks with NewYork-Presbyterian physicians from Columbia & Weill Cornell Medicine about how they are solving some of the most challenging and complex cases in medicine. Together, they discuss groundbreaking discoveries, novel treatments, and the dedication to providing compassionate patient care. This is a show for medical professionals interested in how cutting-edge research and innovations are transforming the future of health care. For more information visit nyp.org/Advances…

Advances in Care

1
Introducing Health Matters: How the Gut is the Connection Between Digestive Health and Mental Health 14:29

vor 1 year14:29

14:29

On this episode of Health Matters, Faith Salie talks with Dr. Benjamin Lebwohl, a gastroenterologist at NewYork-Presbyterian and Columbia. He’s also the Director of Clinical Research at Columbia’s Celiac Disease Center, and an expert on the connections between gastrointestinal health and the other systems in our body that rely on good digestion for their function. He describes how GI diseases like Celiac have implications for mental health, and what anyone can do to support their digestive health.…

Willkommen auf Player FM!

Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.